Loading...
•
Sep 30, 2021
Ultralife Q3 2021 Earnings Report
Reported an operating loss due to supply chain bottlenecks which extended manufacturing schedules and delayed shipments.
Key Takeaways
Ultralife Corporation reported a decrease in revenue and operating income for the third quarter of 2021, with an operating loss of $0.8 million on revenue of $21.8 million. The decline was attributed to supply chain bottlenecks and delayed shipments, particularly impacting the government/defense sector, although commercial sales saw an increase.
Revenue decreased by 10.7% compared to the third quarter of 2020, primarily due to a decline in government/defense sales.
Commercial sales increased by 5.1%, driven by a rebound in oil & gas revenue and new ER and thin cell products.
Medical sales grew 11% sequentially over the second quarter.
Backlog at quarter end was substantially higher than at the end of the second quarter.
Revenue by Segment
Forward Guidance
The company anticipates that its strong balance sheet, new product initiatives, and durable customer relationships will support long-term growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...